- Home
- BBIO vs ESS Comparison
BBIO vs ESS Comparison
Compare BBIO & ESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | ESS |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 15.5B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BBIO | ESS |
|---|---|---|
| Price | $74.63 | $249.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 16 |
| Target Price | $86.04 | ★ $281.83 |
| AVG Volume (30 Days) | ★ 1.5M | 409.9K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 10.40 |
| Revenue | $502,076,000.00 | ★ $1,887,345,000.00 |
| Revenue This Year | $88.16 | $1.89 |
| Revenue Next Year | $74.13 | $3.30 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | ★ 126.26 | 6.36 |
| 52 Week Low | $31.77 | $238.46 |
| 52 Week High | $84.94 | $294.09 |
Technical Indicators
Market Signals| Indicator | BBIO | ESS |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 53.47 |
| Support Level | $70.65 | $248.17 |
| Resistance Level | $78.20 | $263.53 |
| Average True Range (ATR) | 2.54 | 4.45 |
| MACD | 0.48 | 1.20 |
| Stochastic Oscillator | 81.78 | 75.26 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 259 apartment communities with over 63,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.